Literature DB >> 22161382

Conservative prevention and management of pelvic organ prolapse in women.

Suzanne Hagen1, Diane Stark.   

Abstract

BACKGROUND: Pelvic organ prolapse is common, and some degree of prolapse is seen in 50% of parous women. Women with prolapse can experience a variety of pelvic floor symptoms. Treatments include surgery, mechanical devices and conservative management. Conservative management approaches, such as giving lifestyle advice and delivering pelvic floor muscle training (PFMT), are often used in cases of mild to moderate prolapse. This is an update of a Cochrane review first published in 2004, and previously updated in 2006.
OBJECTIVES: To determine the effects of conservative management (physical and lifestyle interventions) for the prevention or treatment of pelvic organ prolapse in comparison with no treatment or other treatment options (such as mechanical devices or surgery). SEARCH
METHODS: We searched the Cochrane Incontinence Group Specialised Trials Register (searched 6 May 2010), EMBASE (1 January 1996 to 6 May 2010), CINAHL (1 January 1982 to 10 May 2010), PEDro (January 2009), the UK National Research Register (January 2009), ClinicalTrials.gov (April 2009), Current Controlled Trials register (April 2009), CENTRAL (Issue 1, 2009) and ZETOC (January 2009) and the reference lists of relevant articles. SELECTION CRITERIA: Randomised and quasi-randomised trials in women with pelvic organ prolapse that included a physical or lifestyle intervention in at least one arm of the trial. DATA COLLECTION AND ANALYSIS: Two reviewers assessed all trials for inclusion/exclusion and methodological quality. Data were extracted by the lead reviewer onto a standard form and cross checked by another. Disagreements were resolved by discussion. Data were processed as described in the Cochrane Handbook for Systematic Reviews of Interventions. MAIN
RESULTS: Six trials were included; three of these trials are new to this update. Four trials were small (less than 25 women per arm) and two had moderate to high risk of bias. Four trials compared PFMT as a treatment for prolapse against a control group (n = 857 women); two trials included women having surgery for prolapse and compared PFMT as an adjunct to surgery versus surgery alone (n = 118 women).PFMT versus controlThere was a significant risk of bias in two out four trials in this comparison. Prolapse symptoms and women's reports of treatment outcomes (primary outcomes) were measured differently in the three trials where this was reported: all three indicated greater improvement in symptoms in the PFMT group compared to the control group. Pooling data on severity of prolapse from two trials indicated that PFMT increases the chance of an improvement in prolapse stage by 17% compared to no PFMT. The two trials which measured pelvic floor muscle function found better function (or improvement in function) in the PFMT group compared to the control group; measurements were not known to be blinded. Two out of three trials which measured urinary outcomes (urodynamics, frequency and bother of symptoms, or symptom score) reported differences between groups in favour of the PFMT group. One trial reported bowel outcomes, showing less frequency and bother with symptoms in the PFMT group compared to the control group.PFMT supplementing surgery versus surgery aloneBoth trials were small and neither measured prolapse-specific outcomes. Pelvic floor muscle function findings differed between the trials: one found no difference between trial groups in muscle strength, whilst the other found a benefit for the PFMT group in terms of stronger muscles. Similarly findings relating to urinary outcomes were contradictory: one trial found no difference in symptom score change between groups, whilst the other found more improvement in urinary symptoms and a reduction in diurnal frequency in the PFMT group compared to the control group. AUTHORS'
CONCLUSIONS: There is now some evidence available indicating a positive effect of PFMT for prolapse symptoms and severity. The largest most rigorous trial to date suggests that six months of supervised PFMT has benefits in terms of anatomical and symptom improvement (if symptomatic) immediately post-intervention. Further evidence relating to effectiveness and cost-effectiveness of PFMT, of different intensities, for symptomatic prolapse in the medium and long term is needed. A large trial of PFMT supplementing surgery is needed to give clear evidence about the usefulness of combining these treatments. Other comparisons which have not been addressed in trials to date and warrant consideration include those involving lifestyle change interventions, and trials aimed at prolapse prevention.

Entities:  

Mesh:

Year:  2011        PMID: 22161382     DOI: 10.1002/14651858.CD003882.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  55 in total

Review 1.  Management options for women with uterine prolapse interested in uterine preservation.

Authors:  Nathan Kow; Howard B Goldman; Beri Ridgeway
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

2.  Diagnosis and Therapy of Female Pelvic Organ Prolapse. Guideline of the DGGG, SGGG and OEGGG (S2e-Level, AWMF Registry Number 015/006, April 2016).

Authors:  K Baeßler; T Aigmüller; S Albrich; C Anthuber; D Finas; T Fink; C Fünfgeld; B Gabriel; U Henscher; F H Hetzer; M Hübner; B Junginger; K Jundt; S Kropshofer; A Kuhn; L Logé; G Nauman; U Peschers; T Pfiffer; O Schwandner; A Strauss; R Tunn; V Viereck
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-12       Impact factor: 2.915

3.  Quality of Life, Sexuality, Anatomical Results and Side-effects of Implantation of an Alloplastic Mesh for Cystocele Correction at Follow-up after 36 Months.

Authors:  Christian Fünfgeld; Margit Stehle; Brigit Henne; Jan Kaufhold; Dirk Watermann; Markus Grebe; Mathias Mengel
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-09-25       Impact factor: 2.915

4.  Prevalence of genital prolapse symptoms in primary care: a cross-sectional survey.

Authors:  Jason Cooper; Manjula Annappa; Davina Dracocardos; Wendy Cooper; Sara Muller; Christian Mallen
Journal:  Int Urogynecol J       Date:  2014-11-08       Impact factor: 2.894

5.  Is a "dragging sensation" a symptom of female pelvic organ prolapse?

Authors:  Hans Peter Dietz; Candice Chatel; Ixora Kamisan Atan
Journal:  Int Urogynecol J       Date:  2017-07-21       Impact factor: 2.894

6.  Characterizing pelvic floor muscles activities using magnetomyography.

Authors:  Diana Escalona-Vargas; Sallie Oliphant; Eric R Siegel; Hari Eswaran
Journal:  Neurourol Urodyn       Date:  2018-11-02       Impact factor: 2.696

7.  Surgical interventions for uterine prolapse and for vault prolapse: the two VUE RCTs.

Authors:  Christine Hemming; Lynda Constable; Beatriz Goulao; Mary Kilonzo; Dwayne Boyers; Andrew Elders; Kevin Cooper; Anthony Smith; Robert Freeman; Suzanne Breeman; Alison McDonald; Suzanne Hagen; Isobel Montgomery; John Norrie; Cathryn Glazener
Journal:  Health Technol Assess       Date:  2020-03       Impact factor: 4.014

8.  Pelvic floor muscle weakness: a risk factor for anterior vaginal wall prolapse recurrence.

Authors:  Jeffrey S Schachar; Hemikaa Devakumar; Laura Martin; Sara Farag; Eric A Hurtado; G Willy Davila
Journal:  Int Urogynecol J       Date:  2018-03-19       Impact factor: 2.894

9.  Assessing exercises recommended for women at risk of pelvic floor disorders using multivariate statistical techniques.

Authors:  Tania Tian; Stephanie Budgett; Jackie Smalldridge; Lynsey Hayward; James Stinear; Jennifer Kruger
Journal:  Int Urogynecol J       Date:  2017-09-13       Impact factor: 2.894

10.  Prevention of pelvic floor disorders: international urogynecological association research and development committee opinion.

Authors:  Tony Bazi; Satoru Takahashi; Sharif Ismail; Kari Bø; Alejandra M Ruiz-Zapata; Jonathan Duckett; Dorothy Kammerer-Doak
Journal:  Int Urogynecol J       Date:  2016-03-12       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.